KRAS encodes a GTPase that couples growth factor signalling to the MAPK cascade and other effector pathways. Oncogenic KRAS mutations compromise its GTPase activity, leading to accumulation of KRAS in the active GTP-bound state and thereby to hyperactive signalling that initiates and maintains tumorigenesis 1 . Owing to the high frequency of KRAS mutations in lung adenocarcinoma and other cancers, strategies to inhibit the KRAS protein or to exploit synthetic lethal interactions with a mutant KRAS gene have been widely pursued but have been fraught with technical challenges or produced inconsistent results 2-7 . Conversely, strategies to target key RAS effectors including MAPK pathway components RAF, MEK, and ERK have been hindered by toxicities associated with their sustained inhibition and/or adaptive resistance mechanisms 8-11 .
the concentration of trametinib, indicating that it is MEK dependent (Extended Data Fig. 2b ). Accordingly, inducible knockdown of ERK2, CRAF, and BRAF blocked ERK signalling rebound and reduced clonogenic growth after trametinib treatment ( Fig. 1d and Extended Data Fig. 2c, d) . Similar effects were observed in KRAS-mutant lung cancer cells treated with trametinib and the ERK inhibitor SCH772984 (Fig. 1e, f and Extended Data Fig. 3 ) 14 . These observations emphasize the marked dependency of KRAS-mutant tumours on the MAPK signalling pathway.
In agreement with other studies, KRAS-mutant cells treated with trametinib also displayed compensatory activation of the PI3K and JAK/STAT pathways as assessed by AKT and STAT3 phosphorylation, respectively ( Fig. 1d , e, g and Extended Data Figs 2c, 3b and 4a) 11, 15 . Although the increase in STAT3 phosphorylation was transient (Extended Data Fig. 4a ), AKT phosphorylation was sustained ( Fig. 1g) . In contrast to their effects on ERK signalling rebound, genetic or pharmacological inhibitions of MAPK signalling had little effect on the trametinib-induced increase in pAKT (Fig. 1d , e and Extended Data Figs 2c and 3b). The activation of multiple signalling pathways after trametinib treatment probably reflects a relief in pleiotropic feedback mechanisms produced by hyperactive RAS signalling in KRAS-mutant cells 8,9 . 
FGFR1 mediates adaptive drug resistance
Several RTKs have been implicated in adaptive resistance to RAS pathway antagonist 8, 9, 11, [15] [16] [17] [18] [19] [20] . The identification of FGFR1 shRNAs as trametinib sensitizers raised the possibility that FGFR1 mediates MAPK and PI3K activation in trametinib-treated KRAS-mutant cells. In agreement, treatment of KRAS-mutant lung tumour cell lines with trametinib increased FGFR1 receptor and/or ligand expression together with FGFR pathway activation as assessed by an increase in phosphorylation of the FGFR adaptor protein FRS2 (Fig. 2a, b and Extended Data Figs 2b and 4b-e) 21 . In turn, FGFR1 activation correlated with an increase in the levels of RAS-GTP, phospho-AKT, and phospho-ERK ( Fig. 2b and Extended Data Fig. 4e ), which was prevented by FGFR1 knockdown (Fig. 2c ). Accordingly, FGFR1 shRNAs did not inhibit the proliferation of KRAS-mutant lung cancer, but displayed synergistic inhibitory effects when combined with trametinib ( Fig. 2d , e and Extended Data Fig. 4f, g) .
The combinatorial effects of FGFR1 inhibition and trametinib showed distinct specificities: for example, shRNAs targeting FGFR1 or FRS2, but not those targeting FGFR2 and 3, sensitized KRASmutant lung cancer cells to trametinib ( Fig. 2f and Extended Data Fig. 4h, i) . By contrast, FGFR1 knockdown had little impact on trametinib sensitivity in KRAS wild-type lung cancer cells (Fig. 2g ). While FGFR1 shRNAs synergized with trametinib in two KRASmutant pancreatic cancer cell lines, they showed little activity in trametinib-treated KRAS-mutant colorectal lines (Extended Data Fig. 5a ). Importantly, this genotype and tissue specificity correlated with the ability of trametinib to trigger FRS2 phosphorylation when applied as a single agent (Extended Data Fig. 5b-d) . Therefore, treatment of certain KRAS-mutant tumour types with trametinib induces a dependency on FGFR1 signalling that promotes adaptive drug resistance.
FGFR1 inhibition enhances trametinib effects
We next tested whether therapeutic strategies combining trametinib with an FGFR1 inhibitor could be effective in treating some KRASmutant lung cancers by combining trametinib with ponatinib, an FDA-approved multikinase inhibitor that inhibits FGFR1 and is being tested clinically for activity against FGFR1-amplified lung cancer (Extended Data Fig. 6a ) (ref. 22 and https://clinicaltrials.gov/ show/NCT01935336). Ponatinib had little effect on KRAS-mutant cells but countered the trametinib-induced increase in pFRS2, pERK, and pAKT, and synergized with trametinib in inhibiting cell proliferation ( Fig. 3a -c, and Extended Data Fig. 6b-e ). As observed in our genetic studies, this combination also showed combined activity in human KRAS-mutant pancreatic cancer cells and a Kras-mutant murine lung adenocarcinoma line (Extended Data Fig. 7a-c ), but to a lesser extent in KRAS wild-type lung cancer cells or KRASmutant colon cancer cells ( Fig. 3c) . Although it remains possible that the synergistic effects of this combination involve the ability of ponatinib to target additional kinases, similar results were observed with two other chemically distinct FGFR inhibitors (Extended Data Figs 7d, e and 8a) 23, 24 . Importantly, sensitivity to the combination of trametinib and FGFR inhibition correlated with the degree of pFRS2 induction after trametinib treatment (Extended Data Fig. 8b, c) .
While our genetic and pharmacological studies establish the importance of the MAPK pathway in adaptive resistance to trametinib, 
Figure 1 | Suppression of MAPK signalling effectors and FGFR1
sensitizes KRAS-mutant lung cells to trametinib. a, Relative abundance of each shRNA in the library in vehicle-or trametinib-treated H23 cells after ten population doublings on doxycycline. The mean of three (vehicle) and two (trametinib) replicates is plotted. Positive and negative controls included shRNAs targeting RPA1 and CDK11A (red circles), and renilla (REN) luciferase (green circles). b, Quantification of fluorescent cells in competitive proliferation assays in H23 cells transduced with non-targeting control (Ren) or the indicated shRNAs. Data presented as mean (n = 2). *P < 0.05, **P < 0.01 (unpaired two-tailed t-test we reasoned that the compensatory increase in PI3K/AKT signalling also plays a role and that its inhibition by ponatinib contributes to the effects of this drug combination. Accordingly, PTEN knockdown, which can increase PI3K signalling independently of RTK activation, promoted partial resistance to the drug combination in KRAS-mutant H2030 cells. This effect was not observed in H460 cells, a KRAS-mutant line that also harbours an activating mutation in the p110α catalytic subunit of PI3K ( Fig. 3d and Extended Data Fig. 9a -c). Consistent with a role for PI3K signalling in promoting cell survival, co-treatment of H23 cells with trametinib and ponatinib triggered substantial apoptosis in a manner that was not observed after treatment with trametinib alone or in combination with an ERK inhibitor ( Fig. 3e and Extended Data Fig. 9d ). Thus, the combined ability of ponatinib to impact reactivation of the MAPK and PI3K pathways contributes to its combinatorial activity in KRAS-mutant lung cancer cells. We also tested whether other RTKs known to be reactivated after MAPK inhibition contribute to adaptive resistance to trametinib in KRAS-mutant lung cancer cells 8, 9, 11, [16] [17] [18] [19] [20] 25, 26 . While trametinib treatment of H23 and H2030 cells increased MET and ERBB2 (but not EGFR) levels (Extended Data Fig. 9e -g), inhibitors targeting these kinases did not synergize with trametinib under the conditions tested ( Fig. 3f and Extended Data Figs 9h and 10a, b). Consistent with previous reports 11 , the dual EGFR/ERBB2 inhibitor afatinib also showed combinatorial activity with trametinib in some KRAS-mutant lung cancer lines, although in our hands less robustly than the trametinib and ponatinib combination ( Fig. 3f and Extended Data Figs 9h and 10a, b). Accordingly, none of the agents tested prevented the rebound in ERK signalling after trametinib treatment ( Fig. 3g and Extended Data Fig. 10c, d) . Thus, reactivation of FGFR1 signalling is a prominent mechanism of adaptive resistance to trametinib in KRASmutant lung cancer cells.
In vivo effects of MEK/FGFR1 inhibition
We validated our in vitro results in KRAS-mutant lung cancer xenografts, a KRAS-mutant patient-derived xenograft, and a genetically engineered mouse model (GEMM) of Kras G12D -induced lung adenocarcinoma that accurately resembles the human disease 27 . A549 and H23 xenografts harbouring tet-responsive FGFR1-or control-shRNAs were treated with doxycycline and a daily dose of 3 mg/kg body weight of trametinib when tumours reached ~150 mm 3 . While knockdown of FGFR1 or treatment with trametinib alone had only minor antitumour effects, the combination of FGFR1 knockdown with trametinib potently inhibited tumour growth and typically caused tumour regression (Extended Data Fig. 11a, b ). Treatment of the xenografts, PDX and GEMM models with vehicle, trametinib, ponatinib, or the drug combination showed similar results, with only the combination producing marked tumour regressions despite no apparent toxicities (Fig. 4a-c and Extended Data Fig. 11c-e ). Moreover, histological analysis of the residual tumour mass in GEMMs treated with the drug combination showed massive necrosis, an effect not seen with either agent alone ( Fig. 4d) . Similar results were observed in an organoid-based, transplantable model of Kras G12D -driven pancreatic cancer, in which the drug combination produced marked cell death and significantly enhanced survival ( Fig. 4e and Extended Data Fig. 11f ).
We also examined the ability of trametinib to induce FGFR1 signalling in KRAS-mutant tumours. Consistent with in vitro results, a KRASmutant lung PDX model showed a concomitant increase in FRS2, ERK, and AKT phosphorylation after trametinib treatment-an effect that was cancelled by ponatinib ( Fig. 5a and Extended Data Fig. 11g ). Furthermore, FRS2 phosphorylation was dramatically increased after trametinib treatment in two patients with KRAS-mutant lung adenocarcinoma ( Fig. 5b) , indicating that the mechanism of adaptive resistance identified in our preclinical models is clinically relevant.
Discussion
In summary, by implementing a stringent approach for negative selection shRNA screening, we identified feedback activation of FGFR1 signalling as a prominent mechanism of adaptive resistance to the MEK inhibitor trametinib in KRAS-mutant lung cancer. The mechanism was specific: only shRNAs targeting FGFR1, but not other FGFR family members or other RTKs tested, conferred trametinib sensitivity, and only FGFR1 inhibition blocked compensatory reactivation of both ERK and AKT. In agreement, an unbiased ORF screen identified FGFR1, but not other RTKs, as sufficient to allow proliferation of KRAS-mutant colon cancer cells after KRAS suppression 28 . In our hands, the synergistic effects of the trametinib/FGFR inhibitor combinations were largely restricted to KRAS-mutant lung and pancreatic cancer cells, but not KRAS wild-type lung or KRAS-mutant colon cancer cells. These results strongly associate sensitivity to the combination with the magnitude of FRS2 phosphorylation after trametinib treatment alone and provide a mechanistic foothold to predict and study cell line and tumour variability. Our results provide strong mechanistic support for combining trametinib with FGFR1 inhibitors for treating KRAS-mutant lung cancer and pinpoint a biomarker that might eventually be used to identify other patients likely to benefit from this drug combination. Although careful attention to additive or synergistic toxicities will be required for the clinical implementation of these findings, it seems likely that targeting a specific RTK such as FGFR1 will be more tolerable than targeting more pleiotropic factors such as AKT 29 and presents a rationale for developing more specific FGFR1 antagonists. Regardless, our study provides further evidence that targeting adaptive resistance mechanisms can improve the efficacy of molecular targeted therapies and provides one path towards developing rational strategies for treating KRAS-mutant lung cancer.
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MethOdS
Pooled negative-selection RNA interference screening. A custom shRNA library targeting 526 human kinases was designed using miR30-adapted DSIR predictions refined with 'sensor' rules 30 (six shRNAs per gene) and constructed by PCR-cloning a pool of oligonucleotides synthesized on customized arrays (Agilent Technologies and CustomArray) as previously described ( Supplementary  Table 1 ) 12 . The list of genes was obtained from the KinBase Database (http://kinase. com/human/kinome/) and was manually curated. After sequence verification, 3,156 shRNAs (5-6 per gene) were combined with 20 positive-and negativecontrol shRNAs at equal concentrations in one pool. This pool was subcloned into the TRMPV-Neo vector and transduced in triplicates into Tet-on H23 KRASmutant lung cancer cells using conditions that predominantly led to a single retro viral integration and represented each shRNA in a calculated number of at least 1,000 cells. Transduced cells were selected for 6 days using 1 mg ml −1 G418 (Invitrogen); at each passage more than 30 million transduced cells were maintained to preserve library representation throughout the experiment. After drug selection, T 0 samples were obtained (~30 million cells per replicate (n = 3)) and cells were subsequently cultured in the presence or absence of trametinib (25 nM) and 1 μg ml −1 doxycycline to induce shRNA expression. After ten population doublings (Tf), about 15 million shRNA-expressing (dsRed + / Venus + ) cells were sorted for each replicate using a FACSAriaII (BD Biosciences). Genomic DNA from T 0 and Tf samples was isolated by two rounds of phenol extraction using Phase Lock tubes (5 Prime) followed by isopropanol precipitation. Deep-sequencing template libraries were generated by PCR amplification of shRNA guide strands as previously described 12 . Libraries were analysed on an Illumina Genome Analyzer at a final concentration of 8 pM; 50 nucleotides of the guide strand were sequenced using a custom primer (miR30EcoRISeq, TAGCCCCTTGAATTCCGAGGCAGTAGGCA). To provide a sufficient baseline for detecting shRNA depletion in experimental samples, we aimed to acquire >500 reads per shRNA in the T 0 sample, which required more than 20 million reads per sample to compensate for disparities in shRNA representation inherent to the pooled plasmid preparation or introduced by PCR biases. With these conditions, we acquired T 0 baselines of >500 reads for 3,151 (97.9%) shRNAs. Sequence processing was performed using a customized Galaxy platform 31 .
Using selection criteria that required an shRNA depletion averaging greater than fourfold after ten population doublings and an effect greater than fourfold in trametinib-treated cells with respect to untreated ones, 64 shRNAs were identified. The eight targets for which at least two shRNAs were selectively depleted after trametinib treatment were subject to secondary validation in cell competition assays using multiple KRAS-mutant lung cancer cell lines. Six targets validated in the cell line in which the primary screen was performed (H23 cells) and four (BRAF, CRAF, ERK2, and FGFR1) across a panel of KRAS-mutant lung cancer cells; as such, these represented the top hits of our screen. Plasmids and recombinant proteins. All vectors were derived from the Murine Stem Cell Virus (MSCV, Clontech) retroviral vector backbone. miR30-and mirEbased shRNAs were designed and cloned as previously described 12 and sequences are available in Supplementary Table 1 . shRNAs were cloned into the TRMPV-Neo (pSIN-TREdsRed-miR30-PGK-Venus-IRES-NeoR), LT3GEPIR (TRE3G-GFP-miRE-PGK-PuroR-IRES-rtTA3), and MLP (LTR-miR30-PGK-PuroR-IRES-GFP) vectors as previously described 12 . All constructs were verified by sequencing. Recombinant proteins FGF2 (8910, Cell Signaling), HGF (100-39, Peprotech), EGF (AF-100-15, Peprotech), and NRG1 (100-03, Peprotech) were used at 50 ng ml −1 for 10 min. Cell culture, compounds, and competitive proliferation assays. H23, H460, H2030, H358, H2122, H820, H3255, and A549 cells were provided by R. Somwar and H. Varmus. H2009, HCT116, SW480, SW620, DLD-1, PaTu 8988t, 3T3, MIAPACA-2, and PANC-1 cells were purchased from the American Type Culture Collection (ATCC). H69, H82, HCC-33, and H446 were provided by C. Rudin. H1975, H1650, Ludlu-1, H1703, PC-14, H2170, SK-MES-1, H520, H522, EBC-1, HCC-15, H441, A-427, and H1299 cells were provided by M. Sanchez-Cespedes. Cell lines were not authenticated. Murine KRAS G12D ; p53 R270H cells were derived from a murine lung adenocarcinoma. Cells were maintained in a humidified incubator at 37 °C with 5% CO 2 , grown in RPMI 1640 or DMEM supplemented with 10% FBS and 100 IU ml −1 penicillin/streptomycin. All cell lines used were negative for mycoplasma.
Trametinib (S2673), SCH772984 (S7101), Gefitinib (S1025), Crizotinib (S1068), CP-724714 (S1167), Afatinib (S1011), BGJ398 (S2183), AZD4547 (S2801), and Ponatinib (S1490) were obtained from Selleckchem. Drugs for in vitro studies were dissolved in DMSO to yield 5 or 10 mM stock solutions and stored at −80 °C.
For shRNA experiments, when necessary, human cancer cells were modified to express the ecotropic receptor and rtTA3 by retroviral transduction of MSCV-RIEP (MSCV-rtTA3-IRES-EcoR-PGK-Puro) followed by drug selection (1 μg ml −1 puromycin for 1 week). Cell lines were transduced with ecotropically packaged TRMPV-Neo-shRNA retroviruses or, alternatively, with amphotropically packaged LT3GEPIR-Puro-shRNA lentiviruses, selected with 1 mg ml −1 G418 or 1 μg ml −1 puromycin for 1 week, and treated with 1 μg ml −1 doxycycline to induce shRNA expression.
For competitive proliferation assays, shRNA-transduced cells were mixed with non-transduced cells (8:2) and cultured with doxycycline in the presence or absence of trametinib (25 nM). The relative percentage of Venus + /dsRed + or GFP + cells was determined before (T 0 , blue bars) and after ten population doublings (Tf) (results are relative to T 0 ) (Tf on doxycycline, grey bars; Tf on dox + trametinib, red bars). The quantification of fluorescent cells was monitored on a Guava Easycyte (Millipore). Experiments were performed independently two or three times. Lentiviral production. Lentiviruses were produced by co-transfection of 293T cells with lentiviral-Cre backbone construct and packaging and envelope vectors (psPAX2 and VSV-G), using the calcium phosphate method. Supernatant was collected 48, 60, and 72 h after transfection, concentrated by ultracentrifugation at 24,000 r.p.m. for 120 min and resuspended in an appropriate volume of HBSS solution (Gibco). Clonogenic and apoptosis assay. For clonogenic assays, cells were seeded in triplicate into six-well plates (5 × 10 3 to 10 × 10 3 cells per well) and allowed to adhere overnight in regular growth media. Cells were then cultured in the absence or presence of drug as indicated in complete media for 10-14 days. Growth media with or without drug was replaced every 2 days. Remaining cells were fixed with methanol (1%) and formaldehyde (1%), stained with 0.5% crystal violet, and photographed using a digital scanner. Relative growth was quantified by densitometry after extracting crystal violet from the stained cells using 10% of acetic acid. All experiments were performed at least three times. Representative experiments are shown.
For apoptosis assays, around 1 × 10 6 cells were seeded into 10-cm plates and cultured in the presence or absence of drugs as indicated. After 6 days, apoptosis and cell death were determined using AnnexinV-APC apoptosis detection kit according to the manufacturer's instructions (Affymetrix eBioscience). Data were acquired using a FACS Calibur (BD Biosciences). All experiments were performed independently three times. Quantitative analysis of drug synergy and determination of fold change in sensitivity to trametinib. Drug synergism was analysed using CompuSyn software (version 1.0) (http://www.combosyn.com), which is based on the median-effect principle (Chou) and the combination index-isobologram theorem (Chou-Talalay) 32 . CompuSyn software generates combination index (CI) values, where CI < 0.75 indicates synergism, CI = 0.75-1.25 indicates additive effects, and CI > 1.25 indicates antagonism. Following the instruction of the software, drug combinations at non-constant ratios were used to calculate the combination index in our study.
For calculating the fold change in sensitivity to trametinib, the concentration of trametinib that inhibited cell proliferation by 50% (GI 50 ) was determined for a panel of KRAS wild-type and mutant cancer cell lines in the absence or presence of ponatinib and AZD4547. Experiments were performed independently twice. Immunoblotting and RAS-GTP assay. Phospho-lysis buffer (50 mM Tris pH 7.5, 1% Tween-20, 200 mM NaCl, 0.2% NP-40) supplemented with phosphatase inhibi tors (5 mM sodium fluoride, 1 mm sodium orthovanadate, 1 mm sodium pyrophos phate, 1 mM β-glycerophosphate), and protease inhibitors (Protease Inhibitor Cocktail Tablets, Roche) was used for cell lysis, and protein concentration was determined by a Bradford protein Assay kit (Biorad). Proteins were separated by SDS-PAGE and immunoblotted and transferred to polyvinyl difluoride (PVDF) membranes (Millipore) according to standard protocols. Membranes were immunoblotted with antibodies against pERK T202/Y204 (9101), tERK (9107), pAKT S473 (4060), tAKT (9272), pFRS2 Y436 (3861), pSTAT3 Y705 (9145), pMEK S217/221 (9154), MEK (4694), pMET Y1234/1235 (3077), MET (8198), pERBB2 Y1221/1222 (2243), pEG-FR Y1068 (3777), EGFR (4267), pERBB3 Y1289 (4791), and PTEN (9559) from Cell Signaling; CRAF (SC-227) and BRAF (SC-5284) from Santa Cruz Biotechnology; and KRAS (WH0003845M1) from Sigma in 5% BSA in TBS blocking buffer. After primary antibody incubation, membranes were probed with ECL antirabbit IgG, anti-mouse IgG or anti-goat IgG secondary antibody (1:10,000) from GE Healthcare Life Science and imaged using a FluorChem M system (protein simple). GTP-bound RAS was measured using a CRAF RAS-binding-domain (RBD) pull down and detection kit (8821, Cell Signaling) as instructed by the manufacturer. All immunoblots were performed independently at least twice. qRT-PCR. Total RNA was isolated using TRIZOL (Invitrogen), and complementary DNA was obtained using the TaqMan reverse transcription reagents (Applied Biosystems). Real-time PCR was performed in triplicate in three independent experiments using SYBR Green PCR Master Mix (Applied Biosystems) on the ViiA 7 Real-Time PCR System (Invitrogen). GAPDH or β-actin served as endogenous normalization controls. Animal studies. All mouse experiments were approved by the Memorial Sloan Kettering Cancer Center (MSKCC) Animal Care and Use Committee (protocol number 12-04-006). Mice were maintained under specific pathogen-free conditions, and food and water were provided ad libitum. Female 5-to 7-week-old athymic NCR-NU-NU (Harlan Laboratories) mice were used for animal experiments with human cell lines and patient-derived xenografts. For A549, H23, and H2122 xenografts, cells (10 × 10 6 ) were harvested on the day of use and injected in growth-factor-reduced Matrigel/PBS (50% final concentration). One flank was injected subcutaneously per mouse. For JHU-LX55a patient-derived xenograft, a poorly differentiated lung adenocarcinoma bearing a KRAS G12C mutation, tumours were cut into pieces and inserted into a pocket in the subcutaneous space as previously described 33 . After inoculation, mice were monitored daily, weighed twice weekly, and calliper measurements begun when tumours became visible. Tumour volume was calculated using the following formula: tumour volume = (D × d 2 )/2, in which D and d refer to the long and short tumour diameter, respectively. When tumours reached a size of 150-300 mm 3 , mice were randomized into five to eight per group and treated with vehicle, trametinib, and/or ponatinib per os for 4 consecutive days followed by 3 days off treatment, at 3 mg/kg body weight and 30 mg/ kg body weight, respectively. No obvious toxicities were observed in the vehicle-or drug-treated animals as assessed by difference in body weight between vehicle-and drug-treated mice taking tumour size into account. For immunohistochemistry analysis of JHU-LX55a patient-derived xenograft tumours, tumours were harvested 4 h after dosing on day 18.
For drug efficacy studies using a GEMM of lung cancer, Kras LSL-G12D/+ and Trp53 fl/fl mice (8-12 weeks old) were anaesthetized by intraperitoneal injection of ketamine (80 mg per kg body weight) and xylazine (10 mg per kg body weight) and infected intratracheally with 2.5 × 10 5 infectious particles of Lenti-Cre per mouse, as previously described 34 . Mice were evaluated by micro-computed tomography imaging to quantify lung tumour burden before being assigned to various treatment study cohorts. Mice were treated with vehicle, trametinib and/or ponatinib per os for 4 consecutive days followed by 3 days off treatment, at 3 mg/kg body weight and 30 mg/kg body weight, respectively. Micro-computed tomography imaging evaluation was repeated every week during the treatment. Investigators were not blinded with respect to treatment.
For drug efficacy studies using an organoid-derived murine model of pancreatic cancer, spherical, duct-like organoids were derived and cultured in Matrigel and defined media as previously described 35 from pancreatic ductal adenocarcinoma (PDAC) occurring in Kras LSL-G12D/+ ; Trp53 fl/+ ; CHC (untargeted collagen homing cassette); RIK (Rosa26-LSL-rtTa3-IRES-Kate2); p48Cre mice (GEMM-KPC fl/+ ) generated via the PDAC-GEMM-ESC approach 36 . After initially establishing primary organoid cultures, Kate-positive cells were sorted and expanded to minimize injection of non-recombined, normal duct cells. For the orthotopic transplantation of PDAC organoids, mice were anaesthetized using isoflurane, and the pancreas was externalized through a small incision made in the left abdominal side near the spleen. Organoids (approximately 250,000-500,000 cells per mouse) were removed from Matrigel and separated into single cells by trypsinization, washed, and finally resuspended in 25 μl of Matrigel (BD) diluted 1:1 with cold PBS. The organoid suspension was injected into the tail region of the pancreas using 28-gauge surgical syringes (Hamilton). Successful injection was verified by the appearance of a fluid bubble without signs of intraperitoneal leakage. The abdominal wall was sutured with absorbable Vicryl suture (Ethicon), and the skin was closed with wound clips (CellPoint Scientific). Mice were evaluated by ultrasound (Vevo 2100, VisualSonics) to quantify pancreas tumour burden before being randomized to various treatment study cohorts. All the treatment mice had similar initial tumour burden. Mice were treated as described above for drug efficacy studies using a GEMM of lung cancer. Investigators were not blinded with respect to treatment. Micro-computed tomography imaging. Micro-computed tomography scans were performed on a Mediso Nano SPECT/CT System covering only the lung fields of each mouse. Each scan averaged approximately 6 min using 240 projections with an exposure time of 1,000 ms set at a pitch of 1°. The tube energy of the X-ray was 55 kVp and 145 μA. The in-plane voxel sizes chosen were small and thin creating a voxel size of 73 μm × 73 μm × 73 μm. The final reconstructed image consisted of 368 voxels × 368 voxels × 1,897 voxels. Scans were analysed with Osirix software. Patients' samples. Patients with KRAS mutation-positive advanced lung adenocarcinomas were enrolled in the phase I/II clinical study of trametinib and navitoclax (NCT02079740) and the response was assessed per RECIST (response evaluation criteria in solid tumours) criteria. Biopsies were obtained before treatment, and within 2-4 weeks after starting the treatment with trametinib. Specifically, for patient 1, the post-treatment biopsy was obtained after treatment with navitoclax for 7 days, followed by co-treatment with navitoclax and trametinib for 16 days. The post-treatment biopsy from patient 2 was obtained after co-treatment with navitoclax and trametinib for 22 days. All human studies were approved by the Massachusetts General Hospital Institutional Review Board, and informed consent to study was obtained as per protocol from all patients. Immunohistochemistry. Tissues were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and cut into 5 μm sections. Sections were subjected to haematoxylin and eosin staining, and immunohistochemical staining following standard protocols. The following primary antibodies were used: pERK T202/Y204 (4370) and pAKT S473 (4060) (Cell signaling), and pFRS2 Y436 (ab193363) (Abcam). Statistical analysis. Data are expressed as mean ± s.e.m. or mean ± s.d. Group size was determined on the basis of the results of preliminary experiments and no statistical method was used to predetermine sample size. The indicated sample size (n) represents biological replicates. Group allocation and outcome assessment were not performed in a blinded manner. All samples that met proper experimental conditions were included in the analysis. Survival was measured using the Kaplan-Meier method. Statistical significance was determined by Student's t-test, log-rank test, and Pearson's correlation using Prism 6 software (GraphPad Software). Significance was set at P < 0.05.
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Extended Data Figure 3 | ERK inhibitor SCH772984 enhances the antiproliferative effects of trametinib in KRAS-mutant lung cancer cells. a, Clonogenic assay of H2030 (upper) and H460 (lower) cells treated with increasing concentrations of trametinib, ERK inhibitor SCH772984, or their combination as indicated. Percentage inhibition at each concentration of the drugs in H23, H2030, and H460 cells is presented (right). Data presented as mean of three independent experiments (n = 3). b, Immunoblot analysis of H2030 cells treated with trametinib (25 nM), SCH772984 (500 nM), or their combination for the times shown. H2030 cells were pre-treated with trametinib for 4 days, followed by treatment with SCH772984 and trametinib for 2 days. c, Cell viability of H23, H2030, and H460 cells treated with increasing doses of trametinib, ERK inhibitor SCH772984, or their combination for 10 days. Data presented as mean ± s.d. (n = 3). The GI 50 was calculated in the absence or the presence of increasing concentrations of SCH772984 (bottom). For gel source data, see Supplementary Fig. 1 . Source Data for Extended Data Fig. 3 are available in the online version of the paper.
Extended Data Figure 5 | Trametinib-induced phosphorylation of FRS2 predicts sensitivity to MEK and FGFR1 combined inhibition. a, Competitive proliferation assays in the indicated KRAS-mutant cancer cell lines transduced with doxycycline-inducible non-targeting control (Ren) or FGFR1 shRNAs. Data presented as mean ± s.d. (n = 3). b, A panel of lung (H1975, H1650, Ludlu-1, H1703, and H1299), pancreas (MIAPACA, PANC1), and colorectal (SW620, SW480, and DLD1) cancer cell lines were treated with 25 nM trametinib for various times. Lysates were subject to immunoblot analysis with the indicated antibodies. c, Scatter plot illustrating the correlation between depletion of FGFR1 shRNAs-expressing cells and fold change in FRS2 phosphorylation after trametinib treatment in human cancer cells lines (n = 15). d, Representation of the fold change in FRS2 phosphorylation after treatment with trametinib for 12 days in human cancer cell lines (n = 15). a, d, Unpaired two-tailed t-test. c, Two-tailed Pearson's correlation. **P < 0.01, ***P < 0.001, ****P < 0.0001. For gel source data, see Supplementary Fig. 1 .
Extended Data Figure 7 | Distinct FGFR1 inhibitors sensitize murine and human KRAS-mutant cancer cells to trametinib. a, Clonogenic assay of a murine lung cancer cell line harbouring Kras G12D and Trp53 R270H mutations (KP cell line), and human KRAS-mutant pancreatic cancer cell lines (MIAPACA and PANC1). Tumour cells were cultured with increasing concentrations of trametinib, ponatinib, or their combination as indicated. b, Percentage of cell growth inhibition at each concentration of trametinib, ponatinib, or their combination in KP, MIAPACA, and PANC1 cells is shown. Data presented as mean of three independent replicates (n = 3). c, Combination index scores for KP, MIAPACA, and PANC1 cells treated with trametinib in combination with ponatinib at the indicated concentrations. Each combination index score represents data from at least three independent experiments (n = 3). d, Clonogenic assay of H23, H2030, and H460 cells cultured with increasing concentrations of trametinib alone or in combination with FGFR1 inhibitors BGJ398 (1.5 μM) or AZD4547 (2 μM). e, Percentage of cell growth inhibition at each concentration of trametinib alone or in combination with BGJ398 (1.5 μM) or AZD4547 (2 μM) in H23, H2030, and H460 cells is shown. Data presented as mean of three independent replicates (n = 3). Source Data for Extended Data Fig. 7 is available in the online version of the paper
